Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412855 | 1.00 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL2411230 | 0.93 | SMN1; SMN2 (0.35) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL2416397 | 0.93 | SMN1; SMN2 (0.35) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL2411228 | 0.93 | SMN1; SMN2 (0.35) | PDE4APDE4BPDE4CPDE4DGAA | |
| SCHEMBL2414387 | 0.87 | DPP4 (0.34) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2414384 | 0.87 | DPP4 (0.34) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2409338 | 0.86 | IRAK1 (0.30) | IRAK1 | |
| SCHEMBL2409341 | 0.86 | IRAK1 (0.30) | IRAK1 | |
| SCHEMBL2415501 | 0.86 | PDCD1LG2 (0.30) | CD274PDCD1LG2 | |
| SCHEMBL2415505 | 0.86 | PDCD1LG2 (0.30) | CD274PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | PDE4A 1370/4885PDE4B 1360/4885PDE4C 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.